scholarly article | Q13442814 |
P356 | DOI | 10.1002/AJH.20641 |
P698 | PubMed publication ID | 16680735 |
P50 | author | Andrea Piccin | Q50214605 |
P2093 | author name string | Francesco Rodeghiero | |
Eros Di Bona | |||
Francesca Elice | |||
Alberto Tosetto | |||
Roberto Raimondi | |||
Anna D'Emilio | |||
P433 | issue | 6 | |
P304 | page(s) | 426-431 | |
P577 | publication date | 2006-06-01 | |
P1433 | published in | American Journal of Hematology | Q4744246 |
P1476 | title | Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | |
P478 | volume | 81 |
Q37677935 | Current multiple myeloma treatment strategies with novel agents: a European perspective |
Q36612669 | Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma |
Q37829230 | Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation |
Q26771331 | Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity |
Q35569350 | Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities |
Q34473121 | Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? |
Q38970595 | Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma |
Q47196540 | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. |
Q64883977 | Multiple Myeloma: Updates on Diagnosis and Management. |
Q38261677 | Novel agents and new therapeutic approaches for treatment of multiple myeloma. |
Q48178842 | Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft |
Q37391117 | Role of autologous and allogeneic stem cell transplantation in myeloma |
Q37738474 | Role of autologous stem cell transplantation in multiple myeloma |
Q44758991 | Second auto-SCT for treatment of relapsed multiple myeloma |
Q46745193 | Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial |
Q41819684 | Stem cell transplantation for multiple myeloma |
Q36556492 | The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma |
Q26851202 | Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers |
Q37949201 | Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. |
Q64900417 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. |
Search more.